In Reply

Debra L. Richardson; Robert L. Coleman; Michael W. Sill

doi:10.1001/jamaoncol.2018.1712

In Reply

Debra L. Richardson, Robert L. Coleman, Michael W. Sill

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1299
Number of pages	1
Journal	JAMA Oncology
Volume	4
Issue number	9
DOIs	https://doi.org/10.1001/jamaoncol.2018.1712
State	Published - Sep 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2018.1712

Cite this

@article{7957c1a0f55a48baacdd89a6aafb2235,

title = "In Reply",

author = "Richardson, {Debra L.} and Coleman, {Robert L.} and Sill, {Michael W.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported. Funding Information: Conflict of Interest Disclosures: Dr Richardson has received honoraria for advisory boards from Genentech and AstraZeneca. Dr Coleman has grant support from Roche/Genentech, AstraZeneca, Clovis, AbbVie, Merck, and Janssen. No other disclosures are reported. 1. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018;4(2):196-202. doi:10.1001/jamaoncol.2017.4218 2. Pignata S, Lorusso D, Scambia G, et al; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561-568. doi:10.1016/S1470-2045(15)70115-4 3. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489 4. Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35-41. doi:10.4137/CMO.S38204",

year = "2018",

month = sep,

doi = "10.1001/jamaoncol.2018.1712",

language = "English (US)",

volume = "4",

pages = "1299",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - In Reply

AU - Richardson, Debra L.

AU - Coleman, Robert L.

AU - Sill, Michael W.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported. Funding Information: Conflict of Interest Disclosures: Dr Richardson has received honoraria for advisory boards from Genentech and AstraZeneca. Dr Coleman has grant support from Roche/Genentech, AstraZeneca, Clovis, AbbVie, Merck, and Janssen. No other disclosures are reported. 1. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018;4(2):196-202. doi:10.1001/jamaoncol.2017.4218 2. Pignata S, Lorusso D, Scambia G, et al; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561-568. doi:10.1016/S1470-2045(15)70115-4 3. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489 4. Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35-41. doi:10.4137/CMO.S38204

PY - 2018/9

Y1 - 2018/9

UR - http://www.scopus.com/inward/record.url?scp=85053429329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053429329&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.1712

DO - 10.1001/jamaoncol.2018.1712

M3 - Letter

C2 - 29978183

AN - SCOPUS:85053429329

SN - 2374-2437

VL - 4

SP - 1299

JO - JAMA Oncology

JF - JAMA Oncology

IS - 9

ER -

In Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this